Go to Top

Blog Archives

Calvert Holdings, Inc. Elects Dr. Donald A. Edmondson to its Board of Directors

Cary, N.C, (May 27, 2015) – Calvert Holdings, Inc., a privately held company focused on servicing early stage drug development companies, announced the election of Dr. Donald A. Edmondson, M.D. to its Board of Directors. Dr. Edmondson is a practicing anesthesiologist in the Raleigh, NC area and is a partner with the American Anesthesiology of North Carolina group. “I have known Don for many years and have found him to …Read More

Calvert Holdings, Inc. Announces Executive Management Changes

CARY, NC (April 1, 2014).  Calvert Holdings, Inc. announced that Michael A. Recny, Ph.D., has been appointed Chief Executive Officer and has been elected a Director of the Company. He replaces Russ McLauchlan, who will become Executive Chairman and who will also now head the newly formed Executive Committee of Calvert Holdings, which will include Dr. Recny, Allan Reiss, President of Calvert Holdings, Inc., and Charles Spainhour, DVM, Ph.D, the …Read More

Calvert Research Portfolio Company Oncoceutics, Inc. Receives FDA Clearance to Begin Phase I/II Trial of ONC201

CARY, NC (March 13, 2014): Calvert Research, LLC, a business unit of Calvert Holdings, Inc., announced that the U.S. Food and Drug Administration (FDA) recently accepted the Investigational New Drug (IND) application for the Phase I/II trial of ONC201, the lead experimental drug compound being developed by Oncoceutics, Inc., a Calvert Research portfolio company.  ONC201 will initially be studied in Phase I safety and dose ranging clinical studies in patients suffering from advanced …Read More

Calvert Research And Oncoceutics Announce Investment Partnership To Advance ONC201 To An IND Filing

CARY, NC and HUMMELSTOWN, PA (October 1, 2013). Calvert Research, LLC, a business unit of Calvert Holdings, Inc., and Oncoceutics, Inc. announced the execution of an Investment Partnership Agreement to support completion of preclinical studies for ONC201, Oncoceutics’ experimental anti-cancer compound. Under the terms of the Agreement, Calvert Research will utilize the extensive resources of its CRO affiliate, Calvert Laboratories, Inc., to complete animal pharmacology, toxicology, and pharmacokinetic testing and conduct bioanalytical …Read More

Calvert Research Awarded Federal Grants to Support Further Development of Its Drug Candidate

Cary, NC–Calvert Research, LLC announced today that one of the Company’s therapeutic development programs (T1-1081) qualified to receive federal grant funding totaling approximately $245,000 under the Patient Protection and Affordable Care Act of 2010 (“The ACT”), which will be used to help advance T1-1081 toward an IND application filing. The Act created a $1.0 billion federal program to provide grants or tax credits to help support certain “Qualifying Therapeutic Discovery …Read More

Calvert Holdings Announces Executive Changes for Calvert Research

April 8, 2010: Calvert Holdings, Inc. announced today a restructuring of executive responsibilities within in its Calvert Research, LLC business unit, effective April 1st, 2010. Michael A. Recny, Ph.D. has been appointed as President of Calvert Research, LLC, assuming the position currently held by Russ McLauchlan, Chairman & Chief Executive Officer of Calvert Holdings, Inc. “Michael and I have now worked together for several years, and I have come to appreciate that …Read More